Endocrine Abstracts (2017) 49 EP371 | DOI: 10.1530/endoabs.49.EP371

Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome (PCOS)

Marta Kialka1, Tomasz Milewicz1, Anna Wajda1, Patrycja Czekanska1, Barbara Zdzierak1 & Sandra Mrozinska2


1Department of Gynecological Endocrinology, Jagiellonian University, Medical College, Cracow, Poland; 2Department of Metabolic Diseases, Cracow, Poland.


Introduction: The aim of our study was to assess the values of total cholesterol, HDL-C, LDL-C and triglycerides before and after treatment with metformin in patients with polycystic ovary syndrome (PCOS) and normal lean.

Material and methods: 32 patients received metformin 1500 mg/day in three divided doses. Lipids measurements were performed to each patient with PCOS twice: before and after 6 months of treatment with metformin.

Results: In patients with PCOS and normal lean after treatment with metformin we observed: statistically significant lower LDL-C levels (4.16±0.79 mmol/l vs 3.4±0.86 mmol/l, P<0.05) and triglycerides levels (1.8±0.53 mmol/l vs 1.12±0.64 mmol/l, P<0.05). We observed an increase in HDL values and a decrease in total cholesterol values, but these changes were not statistically significant (1.5±0.71 mmol/l vs 1.71±0.69 mmol/l, P=0.09; 5.87±0.92 mmol/l vs 5.69±0.97 mmol/l, P=0.11).

Conclusion: Our study showed that treatment of 1500 mg metformin for about 6 months among PCOS women result in improvement in serum lipids. We observed a significant decrease in LDL-C and triglycerides values after metformin treatment.

Article tools

My recent searches

No recent searches.